Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Adynxx

100 Pine Street, Suite 500
San Francisco, CA 94111
USA
(415) 512-7740
Website Company Summary Management Team
Management

CEO: Rick Orr (12/31/2010)
President/COO/Operations: William Martin (1/31/2012)
General Management: Kimberly Hebert (10/31/2011); Donald C Manning (1/31/2012)
Finance: Dina Gonzalez (2010)
Technology: Julien Mamet (12/31/2010)
Former Employees: Scott Harris
Board

Outside board: (May no longer be on the board) Stan E Abel (SiteOne Therapeutics) Dennis Podlesak (Domain Associates Chairman) Eckard Weber (Domain Associates Partner) Heath Lukatch (TPG Biotech Partner)
Company

Business description: Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery and resolving established chronic pain conditions. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom. Adynxx’s lead compound, AYX1, is an investigational drug designed to reduce acute post-surgical pain and prevent the transition to persistent or chronic pain with a single administration at the time of surgery. Adynxx has successfully completed a safety Phase 1 and two proof-of-concept Phase 2 clinical studies of AYX1. Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.
Capital

Rounds: 3
Recent Fundings: Jan 2017   Jul 2011
Capital raised: 23.8M
Last Round: 16.0M
Ownership: Private  
VCs include: Domain AssociatesTPG Biotech

Last Tweets


 

Last Mentions


Overview
Record updated: Oct 2018
Sector: Biotech
Rounds: 3
Recent Fundings: Jan 2017   Jul 2011
Capital Raised: 23.8M
Last Round: 16.0M
Ownership: Private